RE: Expectations20 Mar 2021 15:51
Mikesilver -
"£25 just seems so far away at the moment"
After the issue of contract info, the price will move swiftly upward.
This will be assisted by the fact that 12% of the company is currently in II hands, maybe more at time of news,
and there are only 70 million shares in issue, - making it easier for the sp to slingshot further.
The fact that there are so few shares is key to me being invested.
We cannot say what level price will reach because it depends on the extent of the good news.
Like others on here I think we can expect something better than phase 2, but nobody knows the extent of anything else.
If an M&A deal is announced at roughly the same date, we can expect two bights at the cherry,
likewise if we are bought out (to highest bidder of course).
Few posters regardless of which board discuss a merger.
Clearly the management wanted to get into transplants, as per our strategy, and we have a good background in developing products used in cancer research.
A Bioinformatic based merger would be really good news from my point of view, but lets see.
If a suitable merger with a partner offering a good synergistic fit were to be found, (looking at the full time Chief Corporate Development Officer - Anthony Dyer here), I could see GM being interested, but I feel that a megapharma might be able to make a better offer.
Lets not forget the ages of Mullis (58) and Crinelli may have an influence on decision making.
It's clear there is interest in large companies buying up the smaller ones at present, but we don't know how much influence the French and British governments policies will have over foreign takeover attempts:
https://www.gov.uk/government/news/new-protections-for-uk-businesses-key-to-national-security-and-fight-against-coronavirus
https://www.skadden.com/insights/publications/2020/05/france-moves-to-protect-strategic-assets
Sign In
Follow the stocks
